{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:16Z","timestamp":1759366516979,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.revmed.2023.10.448","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T04:47:15Z","timestamp":1699591635000},"page":"13-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vascularite syst\u00e9mique s\u00e9v\u00e8re induite par l\u2019ibrutinib"],"prefix":"10.1016","volume":"45","author":[{"given":"M.","family":"Fenot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4754-6435","authenticated-orcid":false,"given":"P.","family":"Woaye Hune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Poiraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2023.10.448_bib0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u00a0\u2013\u00a0a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.revmed.2023.10.448_bib0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.revmed.2023.10.448_bib0060","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1186\/1757-1626-2-7526","article-title":"Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report","volume":"2","author":"Maiti","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.revmed.2023.10.448_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.revmed.2023.10.448_bib0070","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cup.14160","article-title":"Ibrutinib skin toxicities: report of two cases","volume":"49","author":"Bloomquist","year":"2022","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.revmed.2023.10.448_bib0075","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2023.10.448_bib0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.revmed.2023.10.448_bib0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1078155219856422","article-title":"Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia\u00a0\u2013\u00a0case report and literature review","volume":"26","author":"Ghasoub","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.revmed.2023.10.448_bib0045","doi-asserted-by":"crossref","first-page":"e14190","DOI":"10.1111\/dth.14190","article-title":"Cutaneous adverse-events in patients treated with Ibrutinib","volume":"33","author":"Pileri","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:13Z","timestamp":1759337233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323012109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0248866323012109"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.10.448","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascularite syst\u00e9mique s\u00e9v\u00e8re induite par l\u2019ibrutinib","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.10.448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}